Latest news
Why Gossamer Bio (GOSS) Is Up 42.9% After FDA Clears Path For Seralutinib NDA Submission - webull.comwebull.com · Fri, 31 Jul 2026 23:08:22 GMTCary company ends $160M drug collaboration - The Business JournalsThe Business Journals · Thu, 30 Jul 2026 11:17:00 GMTGossamer Bio Plans September 2026 Seralutinib NDA After FDA Meeting - Quiver QuantitativeQuiver Quantitative · Mon, 27 Jul 2026 20:57:00 GMTGossamer Reacquires Global Seralutinib Rights From Chiesi, Receives $5 Million - TradingViewTradingView · Mon, 27 Jul 2026 20:03:04 GMTGOSS, Gossamer Bio Updates on Seralutinib and Strategic Developm - GuruFocusGuruFocus · Mon, 27 Jul 2026 17:39:56 GMTGOSS: NDA submission for seralutinib in PAH planned for September 2026, with global rights reacquired - TradingViewTradingView · Mon, 27 Jul 2026 11:13:10 GMTAfter missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration - Fierce BiotechFierce Biotech · Mon, 27 Jul 2026 07:00:00 GMTGossamer Bio Announces FDA Regulatory Update and Reacquisition of Worldwide Rights Related to Seralutinib and Provides a Business Update - Business WireBusiness Wire · Mon, 27 Jul 2026 07:00:00 GMT